Pharma Conference Coverage Strategy

We live in a world of data that threatens to overwhelm our work and personal lives.  Part of the reason for this is the price of data storage continues to fall dramatically.

Today, an external hard drive offers a 1TB capacity; a few years ago the same product offered 100GB.  A 10x increase in storage capacity for the same money in the space of a few years.

Data is now available from online posters, abstracts, webcasts and presentations. We also have Facebook, Twitter, Linkedin and other social media competing for our time.

ASCO 2011 Conference Chicago 300x225 Pharma Conference Coverage StrategyASCO 2011: “the never ending walk”

What this means is that if you plan to attend a major medical or scientific meeting such as the annual meeting of the American Society of Clinical Oncology (ASCO), which offers a lot of data, you need to have a conference coverage strategy.

Here are a few tips we suggest you consider:

Don’t go for a “Data Dump”

Too often we see a “fear of missing out” (FOMO) mentality drive a “we must capture everything” policy.  All this results in is a mass of data that somebody has to analyze after the meeting.  Too often a 300+ page data dump report (when it finally is produced) ends up sitting on the metaphorical shelf.

Focus on Key Questions

Prior to a major medical or scientific meeting it’s important to develop a list of the key questions that a brand, commercial or new products team need answered.  The questions could be on competitor activity, developments in a pathway or impact of clinical data on the standard of care.  Data collection can then be focusoned on answering those key questions.

Insights cost more

Recently, staff at a top 20 pharma company told us they were paying $X for a conference “data dump” but only had 10% of $X available for strategic insights.  In Twitter speak, they had #LostThePlot as it should be the other way round since insights are more valuable than raw data.

As management consultants, we might produce a Powerpoint slide with a table or chart based on data from 20 posters. In order to select those 20 key posters, we could have reviewed perhaps 200 posters originally.  Which would you rather have, one slide with insights and analysis or 200 Powerpoint slides with data? Our philosophy is “less is more.” 

Insights cost more because it takes in-depth therapeutic area knowledge and expertise to condense data into a meaningful story and make strategic recommendations.

What is your conference coverage strategy for this year? Please contact us if you would like to learn more about our capabilities.

AACR-NCI-EORTC Molecular Targets Meeting San Francisco

The favorite scientific meeting of Sally Church, PhD is the American Association for Cancer Research AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics international conference that alternates each year between Europe and the United States.

AACR Molecular Targets Cancer Therapeutics Meeting Banner AACR NCI EORTC Molecular Targets Meeting San FranciscoThis year it is being held in San Francisco from November 12-16, 2011, and already AACR has announced that a lot of new data will be presented on early stage new products in development.

On Pharma Strategy Blog, Sally notes the “luminaries” in personalized medicine that she is looking forward to hearing from in San Francisco.

You can read more about the fall cancer conferences that Sally will be attending on Pharma Strategy Blog.

Pieter Droppert on Biotech Strategy Blog also mentions the Molecular Targets conference and his interest in the plenary session chaired by Frank McCormick on “rational cancer drug development for targeted drugs.”

The potential for academia to facilitate combination trials with drugs from different companies was highlighted in Sally Church’s recent video interview with Gordon B Mills, MD PhD from UT MD Anderson Cancer Center.

If you have plans to be in San Francisco for the Molecular Targets conference do let us know. In addition to hearing about great science – networking and meeting people is one of the big reasons to attend.

Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

Next week sees the start of the 2011 Stockholm Cancer Congress – a joint multidisciplinary meeting of ECCO, ESMO and ESTRO.

What’s likely to be hot news from Stockholm? On Biotech Strategy Blog, Pieter Droppert has highlighted the phase III data to be presented at ECCO 2011 on Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC).

Screen shot 2011 09 17 at 10.52.12 AM Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

The prostate cancer market is set to become interesting from a commercial and marketing strategy perspective, with several new products in late phase development for CRPC including MDV3100, TAK-700, lenalidomide, Alpharadin, custirsen, Prostvac to name but a few.  The Alpharadin data from the ALSYMPCA trial will be presented as a late breaking abstract in the presidential session on Saturday September 24th.  Based on the interim data previously released, positive data is expected.

The best abstract at ECCO 2011, however, is the data on hedgehog pathway (Hh) inhibitor, vismodegib in advanced basal cell carcinoma (BCC).  This will also be presented in the presidential session on Saturday 24th.

Screen shot 2011 09 17 at 10.51.54 AM Vismodegib best abstract at ECCO 2011 Stockholm Cancer Congress

Sally Church on Pharma Strategy Blog has written extensively about hedgehog inhibitors and earlier this week wrote about the news that Roche had filed for FDA approval of vismodegib. Given the accolade of “best abstract” and the data presented in the plenary session at the AACR annual meeting earlier this year, we can expect good news for patients who at present have no treatment options.

As Sally notes, vismodegib (GDC-0449) if approved by the FDA, “will offer the first proof of concept for the role of Hedgehog and Smoothend Inhibition in the treatment of cancer.”

Memories of 9/11

Sally Church Kite Flying Liberty Park WTC in Background 225x300 Memories of 9/11Those of us who lived around New York City ten years ago will never forget the sight of the World Trade Center towers coming down. It is forever indelibly etched in our minds.

Many of us had dined at “Windows on the World” or been to the Observation Deck and watched light aircraft flying along the Hudson, below us. Many knew people who did not make it out.

It is a trauma that we will never forget, and Sept 11 is a day of remembrance. However, life is a journey and we must look forwards not back.

Icarus Consultants closed on Labor Day

Bidston Hill Windmill © Pieter Droppert 225x300 Icarus Consultants closed on Labor DayAfter all the “excitement” of hurricane Irene last week in the New Jersey/New York metro area, this weekend offers the Labor Day holiday. It is to many the last hurrah of summer.

According to the United States Department of Labor, the public holiday on the first Monday in September pays tribute to the American worker, “creator of so much of the nation’s strength, freedom, and leadership.”

Economic prosperity and access to healthcare are very much linked with employment in the United States, so it is sad to see the recent poor job creation results.

Icarus Consultants will be closed on Monday, September 5 and will reopen for business on Tuesday. We wish all our current and prospective pharma and biotech consulting clients an enjoyable weekend.

Pfizer Xalkori crizotinib price in line with Zelboraf in melanoma

Xalkori crizotinib logo Pfizer Xalkori crizotinib price in line with Zelboraf in melanomaLate last friday afternoon, Pfizer received FDA approval for Xalkori® (crizotinib) in non-small cell lung cancer (NSCLC). The companion diagnostic test from Abbott was approved at the same time. Sally Church on Pharma Strategy Blog has written about the Xalkori approval and the “wonderful news” this represents for those affected by this disease.

Sally notes that the Xalkori® story “represents another major advance for targeted therapy in a clearly defined subset of patients.” The cost of treatment is $9,600 per month. In addition there will be the cost of screening the majority of NSCLC patients who do not have an abnormal anaplastic lymphoma kinase (ALK) gene. “ALK aberrations typically occur in the order of 4-7% of NSCLC patients.

Sally in her informative Pharma Strategy Blog post also shares the story from Dr Jack West in Seattle of one patient who has been on the drug for 2 years and is now coaching soccer!

Post Glivec/Gleevec, which Sally helped bring to market while at Novartis Oncology, it’s good to see two new highly targeted therapies that will have a major impact on the lives of patients.

Not withstanding the excellent results, it remains to be seen whether the high price of recently approved oncology drugs such as Zelboraf, Adcetris and Xalkori represents a sustainable business model in the long-run.  Drug companies argue that how society spends its healthcare dollars is a matter of public policy and choice by the taxpayers, rather than an issue of how they choose to price their products.

As Pieter Droppert noted on Biotech Strategy Blog last week while writing about the Google/Department of Justice Settlement, many prescription drugs are cheaper in Canada than in the United States. Is it inevitable that the continued rise in the price of oncology drugs in the United States will eventually force some form of price regulation or costing model based on performance metrics such as Quality-Adjusted Life Years (QALY)?

In the meantime, the Xalkori approval is one that Pfizer can be proud of. Despite all that’s been said about the lack of innovation in the pharmaceutical industry, it’s an example of how knowledge of the underlying biology and mechanism of action of a disease can be leveraged in drug development. The result is a new product brought to market within a relatively short period of time.

In addition to Sally Church’s recent post on Pharma Strategy Blog about the crizotinib FDA approval, she previously posted an excellent interview with Dr Ross Camidge on “crizotinb and ALK rearrangements in lung cancer. This is well worth reading if you missed it the first time.

Pharma Drug Development – time for a new strategy and model of innovation?

Chicago Millenium Park 300x225 Pharma Drug Development – time for a new strategy and model of innovation?Innovation is key to the success of any business. Whether it is coming up with the idea of new products or services to offer customers, or better or more efficient ways to do something, innovation is something that all businesses do.

Innovation can be breakthrough, think of Pfizer’s crizotinib for the treatment of ALK-positive advanced non-small cell lung cancer. It can also be incremental e.g. improvements in formulation and drug delivery that may mean fewer doctor visits and better patient adherence.

It is undisputed that the pharmaceutical industry has not received a good return on investment (ROI) from it’s R&D spending over the past ten years.  One only has to look at the number of new products that have come to market during this period.

Several commentators believe the problem has been the strategy for innovation within the industry.   Pieter Droppert on Biotech Strategy Blog has recently written a series about different views on how innovation in drug discovery could be improved:

There is an active debate around innovation and drug development strategy.  Whether the paradigm will shift to a new model remains to be seen.

In the meantime, we at Icarus Consultants are constantly thinking about new ways to offer more value to our clients. That’s something we should all strive to do, whatever business we are in.

Icarus Consultants to attend EAU in Vienna

Black Forest Cake 300x267 Icarus Consultants to attend EAU in Vienna

Photo Werner Kunz via flickr

Icarus Consultants will be at the forthcoming European Urology Association annual meeting in Vienna, Austria from March 18-22, 2011.

If you are going to be in Vienna and would be interested in meeting up for Kaffee Und Kuchen, please contact us.

Incidentally, our favorite is a slice of Schwarzwälder Kirschtorte (Black Forest gateau).

 

Groundbreaking research on identification of ZNF703 oncogene in breast cancer

Sally Church on the Pharma Strategy Blog analyzes the significance of new research that has identified a new oncogene associated with 1 in 12 breast cancers.

Research published by Holland et al, in the journal, EMBO Molecular Medicine, has identified the ZNF703 oncogene to be linked with Luminal B breast cancer.

This is the first oncogene to be discovered in 5 years since HER2, and has tremendous potential as a target for drug development.

As Sally comments on her blog “it’s much easier to design a drug or therapeutic once you have a valid target to aim for and with more specific targeting, comes improved patient outcomes.”

This is important news and Sally’s blog post has more in-depth insight and analysis.